Antimicrobial Therapy in Immunocompromised and Critically Ill Patients: Management and Perspectives


It is a pleasure and a honour for us to welcome you in Lugano for the 4th ATCIP Congress. The Palazzo dei Congressi, conveniently located at walking distance from the Main Station and downtown, is the ideal venue to host a meeting that we hope will be enjoyable and highly educational. The Meeting’s themes are very exciting and comprehensive, aiming  at providing first-hand and up-to-date information on the management of infectious diseases, including diagnostics and the most appropriate antimicrobial therapy, in critically ill patients. 

Immunocompromised and critically ill patients are exposed to viral, bacterial and fungal infections that complicate the already difficult therapy of the underlying diseases. In oncologic patients, new immunobiologicals contribute to the increase of opportunistic infections; in addition, the emergence of resistant viral, bacterial and fungal strains as well as the report of new opportunistic pathogens makes treatment of these patients a daunting task. New antivirals have now expanded the therapeutic options in the treatment of hepatitis B, hepatitis C and HIV. New diagnostic tools as well as antibacterial and antifungal agents are available to support the fight against infectious diseases in the ICU and other clinical settings. On the other hand, viral, bacterial and fungal diseases are still the cause of unacceptably high mortality rates in ICU, oncologic and transplant patients. 

Keynote speakers will highlight the latest progress in research on various aspects of infectious diseases and their diagnosis and therapy in the critically ill. We hope to see you soon in Lugano for what we are sure will be a very enjoyable and highly educational stay.


Many questions related to the diagnosis and treatment of critically ill and immunocompromised patients are still open: this congress will discuss the most common issues and controversies related to the diagnosis and treatment of infectious diseases in these groups of patients, with the aim of providing not only theoretical but also real-life experience to be then translated into daily clinical practice.


Infectious disease and intensive care specialists, rheumatologist, oncologists, healthcare professionals, clinical microbiologists, other health professionals involved in the care of critically ill and immunocompromised patients (haemato-oncologists, transplant specialists).


Luigia Elzi, MD

Locarno, Switzerland

scientific committee

Enos Bernasconi, MD

Lugano, Switzerland

Christian Garzoni, MD

Lugano, Switzerland

Paolo Grossi, MD

Varese, Italy

Oscar Marchetti, MD

Nyon, Switzerland

Orlando Petrini, PhD

Lugano, Switzerland